Colin Broom M.D. is VP & Chief Scientific Officer at VIROPHARMA INC (VPHM). They have made 12 open-market trades across 2 companies since 2008, most recently 2022-08-02.
CIK 0001289946
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
4 open-market purchases totalling $107K since 2017, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NBRV | SELL | 2022-08-02 | 2022-08-04 | $0.19 | $1K | +6.8% | -12.9% | -46.6% |
| NBRV | SELL | 2021-08-02 | 2021-08-04 | $1.20 | $637 | -15.0% | -7.5% | +1.7% |
| NBRV | SELL | 2020-08-20 | 2020-08-21 | $0.65 | $7K | -6.1% | -8.8% | -29.3% |
| NBRV | BUY | 2019-08-30 | 2019-09-03 | $2.03 | $21K | +28.4% | -7.0% | -2.0% |
| NBRV | BUY | 2018-06-22 | 2018-06-25 | $3.72 | $19K | -9.4% | -7.3% | -34.4% |
| NBRV | BUY | 2018-05-23 | 2018-05-23 | $4.60 | $46K | -0.2% | -17.3% | -43.3% |
| NBRV | BUY | 2017-09-22 | 2017-09-26 | $8.35 | $22K | -1.1% | -34.1% | -25.9% |
| NPSP | SELL · 10b5-1 | 2013-02-07 | 2013-02-11 | $8.74 | $53K | N/A | N/A | N/A |
| VPHM | SELL · 10b5-1 | 2012-12-24 | 2012-12-28 | $22.53 | $394K | N/A | N/A | N/A |
| VPHM | SELL | 2012-12-10 | 2012-12-12 | $24.07 | $1.8M | N/A | N/A | N/A |
| VPHM | SELL · 10b5-1 | 2011-12-14 | 2011-12-15 | $25.34 | $1.3M | N/A | N/A | N/A |
| VPHM | SELL · 10b5-1 | 2011-12-12 | 2011-12-14 | $23.50 | $940K | N/A | N/A | N/A |
| VPHM | SELL | 2011-11-07 | 2011-11-08 | $21.00 | $420K | N/A | N/A | N/A |
| VPHM | SELL | 2011-10-31 | 2011-11-02 | $20.22 | $902K | N/A | N/A | N/A |
| VPHM | SELL | 2010-09-09 | 2010-09-13 | $13.26 | $398K | N/A | N/A | N/A |
| VPHM | SELL | 2008-09-12 | 2008-09-16 | $14.25 | $361K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.